Afterglow Dx preserves and commercializes diagnostic technologies and development assets originating from Luminostics, Inc., doing business as Clip Health, a venture-backed biotechnology company founded in 2014.
What began as doctoral research into persistent luminescent nanomaterials at the University of Houston evolved into a multidisciplinary diagnostic technology platform spanning advanced detection chemistry, biological assays, optical instrumentation, software, and regulated medical-device manufacturing.
Development & Commercialization Timeline
2013
Academic Research Origins
The earliest smartphone-based optical detection experiments were conducted in December 2013 during doctoral research at the University of Houston, establishing the foundation for the technology that would become Luminostics.
2014
Luminostics Founded
Luminostics was founded to commercialize persistent luminescent nanoparticle technology and develop new diagnostic applications.
2016
Y Combinator & Venture Investment
Luminostics participated in Y Combinator’s Summer 2016 program and secured venture capital backing, including investment from Khosla Ventures.
2016–2020
NIH-Funded Research & Development
The company advanced its diagnostic platform through scientific research, assay development, optical engineering, software development, and NIH-supported programs, including Phase I and Phase II Small Business Innovation Research (SBIR) awards.
2020
NIH RADx & Commercial Launch
Luminostics / Clip Health received more than $39 million in funding through the NIH Rapid Acceleration of Diagnostics (RADx) program to support COVID-19 diagnostic development and manufacturing scale-up.
The Clip COVID Rapid Antigen Test received FDA Emergency Use Authorization in December 2020, and the first-generation analyzer platform was commercially launched.
2021–2023
Core Analyzer Development
Building upon nearly eight years of accumulated expertise in optical detection, image processing, time-gated imaging, and diagnostic instrumentation, Clip Health began development of Core in 2021.
Core was engineered as a cost-effective, high-performance analyzer platform designed to enable reliable, accessible at-home diagnostic testing at commercial scale, including multiplex respiratory applications for COVID-19 and influenza.
2023–Present
Technology Preservation
Following the cessation of Clip Health operations in 2023, technology and development assets were subsequently acquired and preserved.
Afterglow Dx was established to maintain these assets and facilitate licensing, commercialization, and new strategic applications.
Luminostics founded
Y Combinator
NIH RADx funding
COVID-19 tests shipped
From Academic Research to Commercial Diagnostic Platforms
The technology underlying the Luminostics / Clip Health diagnostic platforms originated in academic research at the University of Houston, with the earliest smartphone-based optical detection experiments conducted in December 2013.
Following the founding of Luminostics in 2014, development continued alongside doctoral research through 2016 before transitioning into a full-time commercial effort. Over the following years, the technology evolved through iterative research, optical and hardware engineering, user testing, human factors and usability engineering, and product development.
This progression involved multiple generations of passive and active smartphone-based detection systems, culminating in the commercial launch of the Clip COVID Rapid Antigen Test analyzer in December 2020.
In 2021, Clip Health began development of Core, leveraging nearly eight years of accumulated expertise in optical detection, image processing, time-gated imaging, instrumentation, and diagnostic system design. Core was engineered as a low-cost, high-performance analyzer platform intended to enable accurate, reliable, and accessible at-home diagnostic testing at commercial scale.
Designed to support multiplex respiratory diagnostics, including COVID-19 and influenza testing, Core represented a significant evolution in the platform’s architecture, translating years of scientific research, engineering development, and user experience into a purpose-built diagnostic instrument.
Together, these two generations demonstrate the progression from early academic experimentation to clinically validated diagnostic platforms, with successive advances in performance, usability, manufacturability, and scalability.
First Generation · 2020
Clip COVID Rapid Antigen Test Analyzer
Smartphone-based optical detection platform developed through years of research, engineering, user testing, and usability evaluation. Commercially launched in December 2020.
Second Generation · Development Began 2021
Core Analyzer
Purpose-built, cost-effective optical analyzer leveraging nearly eight years of expertise in time-gated imaging, image processing, and diagnostic instrumentation, designed for high-performance at-home testing at scale.
Technology Preservation & Commercialization
Luminostics, Inc., doing business as Clip Health, ceased operations in 2023 following nearly a decade of research, technology development, and diagnostic product commercialization.
Following the company’s closure, its technology and development assets were acquired and preserved through Afterglow Dx, Inc., which maintains the assets and serves as the point of contact for licensing, acquisition, and other strategic transactions involving the technology portfolio.
Afterglow Dx holds rights to commercialize acquired assets and negotiate licensing and other commercial arrangements involving associated intellectual property, subject to applicable third-party rights and licensing agreements.
These assets remain available for organizations interested in advancing the underlying technologies, developing new commercial applications, or accessing the historical engineering and scientific development corpus.